SummitTX Capital’s Corcept Therapeutics CORT Stock Holding History

SummitTX Capital’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,648	Closed	-$488K	–	798
2025 Q2	$488K	Buy	+6,648	New	+$482K	0.02%	512

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

SummitTX Capital's CORT Position: Q3 2025 in Review

SummitTX Capital sold out of Corcept Therapeutics (CORT) in Q3 2025, closing a stake of 6,648 shares — an estimated $488K sold.

SummitTX Capital first reported a position in CORT in Q2 2025 and held it in 1 quarter. The position peaked at $488K in Q2 2025. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

SummitTX Capital reported no remaining Corcept Therapeutics position as of Q3 2025 after selling out during the quarter.
SummitTX Capital sold 6,648 Corcept Therapeutics shares in Q3 2025, an estimated $488K.
SummitTX Capital first reported a position in Corcept Therapeutics in Q2 2025 and held it in 1 quarter.
SummitTX Capital's Corcept Therapeutics position peaked at $488K in Q2 2025.
429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on SummitTX Capital's 13F filing for Q3 2025, filed 14 Nov 2025.